A Prospective, Single-Arm, Phase II Trial of QL1706 in Patients With Recurrent and/or Metastatic Cervical Cancer Who Had Developed Resistance to Prior PD-1/PD-L1 Antibody Therapy
Latest Information Update: 08 Sep 2025
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
Most Recent Events
- 08 Sep 2025 New trial record